ABBV Highlighted for M&A-Driven Pipeline Depth Amid Humira Erosion
What happened
The Motley Fool on July 21 outlined three factors it views as supportive for AbbVie shares, centering on the company's acquisition-built post-Humira pipeline, its streak of dividend growth, and its expanding immunology and neuroscience portfolios. AbbVie has executed a series of deals — including the ImmunoGen and Cerevel Therapeutics closings — to replenish revenue as Humira biosimilar competition erodes its legacy base. The piece points to newer drugs such as Skyrizi and Rinvoq as primary growth drivers replacing that lost revenue.
The QL Read
With breadth at 61.1% advancing and ABBV's QuantLogix composite reading 79/100, the stock's pipeline narrative lands in a moderately constructive tape. The +1.07% session gain aligns with the engine's near-term momentum read.